Eng

CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody

PR Newswire (美通社)
更新於 15小時前 • 發布於 15小時前 • PR Newswire

SHANGHAI, Dec. 23, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission of clinical trial application in Australia for CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody), a leading asset from the Company's Pipeline 2.0 to address various solid tumors. This first-in-human study has also been registered and published on Clinicaltrials.gov (NCT number: NCT06741644).

CS2009 features an innovative molecular design that targets PD-1, VEGFA, and CTLA-4 simultaneously, maintaining balanced affinity for PD-1 and CTLA-4. This design enables preferential targeting of double-positive tumor-infiltrating T lymphocytes (TILs), effectively blocking both PD-1 and CTLA-4 while sparing CTLA-4 on single-positive cells. This approach could potentially reduce systemic toxicity without compromising efficacy. Additionally, CS2009 induces high and rapid internalization, leading to the down-regulation of PD-1 and CTLA-4 expression on the TIL cell membrane. Notably, CS2009 retains full VEGF inhibitory function, and preclinical data indicate that its anti-VEGF activity exhibits significant synergistic effects with its immune checkpoint inhibitory functions—crosslinking with VEGFA markedly enhances both anti-PD-1 and anti-CTLA-4 activities.

At the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC Annual Meeting) in 2024, CStone presented compelling preclinical data for CS2009, demonstrating superior anti-tumor activity compared to potential competitors. The data underscored the potential of CS2009 to address a wide range of tumor types, including non-small cell lung cancer, ovarian cancer, renal cell carcinoma, cervical cancer, hepatocellular carcinoma, and gastric cancer. CS2009 is positioned as a potential first-in-class or best-in-class next-generation immuno-oncology backbone.

廣告(請繼續閱讀本文)

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated: "We are excited to announce the timely submission of the Phase I clinical trial application for CS2009, marking another significant milestone in CStone's Pipeline 2.0 strategy. Designed and developed in-house since 2022, CS2009 has evolved into a tri-specific antibody with a novel molecular design and robust preclinical data, holding the potential to replace current anti-PD-(L)1 therapies. Thanks to close collaboration across departments, we have rapidly advanced CS2009 to the clinical stage. The first-in-human study will soon commence in Australia, and we look forward to exploring the potential benefits CS2009 could bring to cancer patients, particularly those with low or negative PD-L1 expression who respond poorly to existing PD-(L)1 treatments."

CStone plans to initiate a multi-regional, first-in-human clinical trial for CS2009 in Australia in early 2025, followed by expansion into China and the United States.

About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

廣告(請繼續閱讀本文)

CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, with the potential to be first- or best-in-class for major tumor types. Its differentiated molecular design combines three clinically validated targets, preferentially invigorating exhausted TILs while demonstrating VEGF neutralization comparable to existing anti-VEGF antibodies. CS2009 covers a wide range of cancers, including non-small cell lung cancer, ovarian cancer, renal cell carcinoma, cervical cancer, hepatocellular carcinoma, and gastric cancer.

In November 2024, CStone presented preclinical data for CS2009 at the 39th SITC Annual Meeting. These results show that CS2009 exhibits superior anti-tumor activity compared to potential competitors, including PD-1/CTLA-4 bispecific antibodies, PD-1/VEGF bispecific antibodies, and PD-1/CTLA-4 combination therapies.

About CStone

廣告(請繼續閱讀本文)

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients' unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company's pipeline is balanced by 17 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit .

IR contact:
PR contact:

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals.

查看原始文章

更多 Eng 相關文章

Trump rejects talk that he's ceded the presidency to Elon Musk
XINHUA
APR Corp. Targets Global Beauty Market Share Expansion with Participation in CES for Two Consecutive Years
PR Newswire (美通社)
WiMi Develops Quantum Error Mitigation Technology Based on Machine Learning
PR Newswire (美通社)
First China-Ethiopia Film, TV Festival opens to promote cultural exchange
XINHUA
EnchantingGuangxi | Ancient buildings well preserved in over 400-year-old hamlet in S China's Guangxi
XINHUA
Miral Announces Ambitious Sustainability Strategy to Advance Responsible Leisure, Entertainment and Tourism
PR Newswire (美通社)
Foxconn Announces Strategic Partnership With Zettabyte to Transform AI Data Centers
PR Newswire (美通社)
GLOBALink | Major policy risks cloud U.S. growth figures
XINHUA
Porton Pharma Solutions and Dragon Sail Pharmaceutical Form Strategic Partnership to Build a New Ecosystem for ADC Drug Development, Production, and Supply Chain
PR Newswire (美通社)
Xinhua News | China has over 4.5 million firms in core industries of digital economy
XINHUA
China urges the Philippines to pull out Typhon missile system as publicly pledged
XINHUA
FlyOverChina | N China's Hohhot embraces high-quality development
XINHUA
JSAUX reveals a new 7-in-1 RGB Docking Station with cooling fans and an RGB ModCase with cool stands for the ROG Ally X
PR Newswire (美通社)
GLOBALink | Foreigners explore Song Dynasty culture in Jiangsu
XINHUA
Trump signals openness to TikTok
XINHUA
Xinhua Headlines: Major policy risks cloud U.S. growth prospects
XINHUA
From Campus to CES®: KHU Startups and Students on a Global Mission
PR Newswire (美通社)
Xinhua News | Yemen's Houthis claim striking U.S. aircraft carrier, downing warplane
XINHUA
Xinhua News | China's 5G subscriptions surpass 1 billion amid strong uptake
XINHUA
Xinhua Commentary: China stands committed to steady development of China-U.S. ties
XINHUA
Xinhua News | Xi presents order to promote military officer to rank of general
XINHUA
Xinhua News | Quality of China's state-owned assets improved significantly: report
XINHUA
Xinhua News | Man sentenced to death with reprieve for driving car into crowd
XINHUA
GCL Energy Technology and Ant Digital Technologies Launch First Blockchain-Based RWA Project in Photovoltaic Industry
PR Newswire (美通社)
Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis
PR Newswire (美通社)
Chinese community, UNESCO support Ghanaian orphanage with donations, renovation
XINHUA
Mega Matrix Announced that "See You Again CEO's Sweet Trap" Premieres on FlexTV December 20th - Can Love Survive the Test of Time?
PR Newswire (美通社)
China's "Kung Fu Pandas" at play
XINHUA